Summit Therapeutics (NASDAQ:SMMT) stock extends gains as lead cancer drug ivonescimab developed with Akeso (AKESF) ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

The collaboration reflects Ebn Sina Medical’s commitment to delivering high-quality medicinal products to the local market, ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

Analysts have set 12-month price targets for BeiGene, revealing an average target of $330.25, a high estimate of $348.00, and a low estimate of $312.00. This current average reflects an increase of 10 ...

Beigene has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Beigene’s peers have a beta of 3.84, meaning that their average stock price is 284% ...

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

Ebn Sina Medical has signed a strategic partnership with BeiGene making it the local partner and distributor for the latter’s range of oncology medicines, enhancing the availability of ...